Skip to content
Explore the latest in technology, digital trends, and insig…

Administering Pluripotent Cells During Pregnancy to Infants with Spina Bifida Boosts Life Outcomes, Research Shows

A groundbreaking clinical study has revealed that administering stem cells to fetuses suffering from spina bifida while undergoing fetal surgery can be a "important advancement" in treating birth defects.

Trial Details and Safety

The US-based trial focused on six developing infants with the 'open' form of spina bifida. Doctors administered placenta-derived mesenchymal stem cells directly onto the baby's spinal cord as part of the surgical correction.

Significantly, the cell therapy proved to be secure. Doctors verified that the treatment did not lead to cancerous growths, interfere with wound healing, or prevent the reversal of related neurological issues.

Encouraging Results

Post-birth MRI scans indicated a full resolution of brainstem displacement in all six infants. This brain structure normalization is a key indicator for better mobility and function.

"Should it enable more children to achieve ambulation who otherwise would not, it could establish itself as their standard of care," said the lead researcher. "The outcomes appear super exciting and open the door to numerous possible new treatments."

Long-Term Prospects and Optimism

Commentators reviewing the findings indicated that further confirmation of these noted improvements could announce a "new era" in fetal surgery. The prospect of enhancing nerve function impairment present before birth is considered a transformative goal.

Particularly welcome would be improvements in bladder and bowel function, which are typical difficulties for individuals living with this defect.

The Path Forward

While this initial trial focused on a handful of cases, its safety demonstration and positive signals offer a robust platform for larger, more comprehensive studies. The combination of regenerative medicine with current in-utero repair procedures holds considerable promise for transforming outcomes for future generations with myelomeningocele.

The writer

Donna Johnson

A tech enthusiast and digital strategist with over a decade of experience in software development and emerging technologies.

Tech Insights Blog

Type to search articles.